To examine the effect of age on the likelihood of PIP of opioids and the effect of PIP on adverse outcomes. DESIGN: Retrospective cohort study. SETTING: Data from multiple state agencies in Massachusetts from 2011 to 2015.
O pioid use and opioid-related harms may be different in older (≥50) and younger adults. 1 Prescription opioids account for more than twice as many deaths as illicit opioids in older adults. 2 Potentially inappropriate prescribing (PIP) involves suboptimal prescribing or high-risk medication use. Research has shown an association between PIP and fatal opioid overdose, [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] and at least one study has shown higher rates of PIP in older than younger adults. 13 Older adults may be particularly vulnerable to toxicity from PIP, given greater pharmacokinetic vulnerability inherent in the aging process. 14 Few studies have characterized patterns of PIP in older adults, and few of these have examined its consequences. This study used the population of Massachusetts over 5 years to address this gap in the literature by examining age as a predictor of PIP and the degree to which age may modify the effect of PIP on adverse events. The results of this study can inform practice-and policy-level interventions to reduce PIP exposure and harms for individuals already exposed to PIP.
METHODS

Database and Participant Sample
We used databases that the Massachusetts Department of Public Health (MDPH) administers under the authority of Chapter 55 legislation. 15 Chapter 55 of the Acts of 2015 mandate that MDPH analyze data from several state agencies and allow for linkage of datasets to analyze trends in opioid-related overdose. 15 The dataset, covering more than 98% of the state's population, included Massachusetts' prescription monitoring program (PMP), all-payer claims database (APCD), mortality records (including autopsy and postmortem toxicology), demographic and area-level socioeconomic status data, and ambulance and emergency medical services (EMS) records.
Our study population included anyone aged 18 and older who filled at least 1 opioid prescription from 2011 to 2015 (N = 3,078,163); we excluded individuals with regionally or distantly disseminated cancer (Supplementary Appendix S1). Prescription opioid analgesics included codeine, fentanyl, hydrocodone, hydromorphone, meperidine, methadone (used as an analgesic), morphine, oxycodone, and oxymorphone (Supplementary Appendix S2). Buprenorphine and methadone used for treatment of opioid use disorder were not considered when assessing prescription opioid exposure 12 , but individuals who received them were not excluded if they also received prescription opioid analgesics. The institutional review boards of MDPH and RAND Corporation exempted the study from review.
Measures
Subtypes of PIP of Opioids. Similar to other studies, [3] [4] [5] [6] [7] [8] [9] [10] [11] we identified exposure to 1 or more types of PIP, including: 
Participant Outcomes
Outcomes included nonfatal opioid overdose, fatal opioid overdose, and all-cause mortality. Nonfatal overdose was identified in EMS data using an MDPH algorithm and inhospital or emergency department encounter data using International Classification of Diseases, Ninth Revision, codes (Supplementary Appendix S4). We considered only the first occurrence of nonfatal overdose. Fatal overdose and all-cause mortality were identified using state mortality data (Supplementary Appendix S5).
Covariates
Sex was defined as male or female. Race and ethnicity were not used as covariates because data were missing in nearly half the cases. Two comorbid conditions that are probably relevant to the development of opioid-related adverse events (major depression, alcohol use disorder) were identified using claims data (Supplementary Appendix S6). We characterized community-level socioeconomic status according to percentage of households below the federal poverty level in the individual's ZIP code of residence. 16 
Statistical Analyses
We used logistic regression to estimate the age-specific odds of any PIP, controlling for covariates, in the population of individuals who received any prescription opioids.
We then stratified the sample into older (≥50) and younger (18-49) adults. For each stratum and outcome (nonfatal overdose, fatal overdose, all-cause mortality), we conducted a separate logistic regression to examine the influence of each PIP subtype on the outcome, controlling for the other subtypes of PIP and individuals-level covariates other than age. Finally, we examined the influence of the number of PIP subtypes to which the individual had been exposed (0, 1, 2, ≥3) on each outcome, controlling for individual -level covariates. For all analyses regarding nonfatal overdoses, exposure to PIP was included only if it had occurred before the overdose event. All analyses were performed using SAS Studio version 3.5 (SAS Institute, Inc., Cary, NC).
RESULTS
Participant Characteristics and Outcomes
Between 2011 and 2015, 3,078,163 adult Massachusetts residents (57% of the state's adult population) received at least 1 opioid prescription; 52% were aged 50 and older. Older opioid recipients were more likely than younger recipients to live in the lowest-poverty ZIP codes (56% vs 47%, p < .001) and somewhat more likely to have major depression (19% v. 16%, p < .001) (Supplementary Appendix S7). All-cause mortality was much higher in the older group (8% vs 0.6% over the 5 years of the study, p < .001), whereas younger individuals had considerably higher rates of fatal (0.2% vs 0.06%, p < .001) and nonfatal (1.0% vs 0.5%, p < .001) opioid overdose.
Age Distribution of PIP of Opioids
The percentage of prescription opioid recipients experiencing any PIP increased with age but plateaued above age 50 ( Figure 1A ). The proportion of individuals experiencing 2 or more PIP subtypes during the study period also varied with age, peaking from age 50 to 59. Prevalence of each PIP subtype had a distinctive age distribution ( Figure 1B) , with most PIP subtypes peaking from age 50 to 59. Receipt of highdose opioids, co-prescription of benzodiazepine, having multiple prescribers, and having multiple pharmacies all peaked from age 50 to 59. High-dose opioids declined somewhat with older age (50-59, 4.0%; ≥80, 2.3%). For benzodiazepine co-prescribing, the decline with age was less pronounced (50-59, 8.5%; ≥80, 6.9%). In contrast to the other PIP subtypes, receiving continuous opioid prescriptions without a pain diagnosis increased monotonically with age, reaching a high of 5.5% in those aged 80 and older.
Individual-Level Predictors of PIP of Opioids
For individuals prescribed any opioid during the study period, the adjusted odds of receiving PIP increased with age (Table 1) , plateauing above age 50 to 59 (aged ≥80: aOR= 6.37 compared with aged 18-29). Women (OR=1.12), individuals with depression (OR=2.73), and individuals with alcohol use disorder (OR=1.88) were also significantly more likely to undergo PIP.
Association Between PIP and Outcomes
PIP was associated with all-cause mortality, fatal opioid overdose, and nonfatal overdose across the study population ( Table 2 ). Most PIP subtypes were associated with greater odds of all-cause mortality in younger adults than older adults. For example, co-prescribing with benzodiazepines was associated with greater odds of all-cause mortality in younger adults (aged 18-49, OR=2.84, 95% CI=2.66-3.03) than older adults (aged ≥50, OR=1.47, 95% CI=1.44-1.50). PIP was generally associated with similar odds of nonfatal and fatal opioid overdose among older adults as among younger adults. For example, benzodiazepine coprescription was associated with fatal overdose (younger adults: OR=4.54, 95% CI=4.03-5.10; older adults: OR=4.53, 95% CI=3.83-5.34).
The effect of multiple subtypes of PIP on all-cause mortality was stronger in younger adults (≥ 3 subtypes of PIP: younger adults: OR=14.95, 95% CI=13.89-16.09; older adults: OR=7.69, 95% CI=7.42-7.97), whereas exposure to multiple subtypes of PIP increased the odds of fatal and nonfatal opioid overdose more markedly in older adults.
DISCUSSION
Prescription opioids are a major cause of opioid-related death, especially in older adults.
2 PIP is associated with higher odds of nonfatal opioid overdose, fatal opioid overdose, and all-cause mortality. [3] [4] [5] [6] [7] [8] [9] [10] [11] In our study, age was by far the strongest predictor of undergoing PIP. We also found that PIP was strongly associated with higher odds of adverse events in older and younger adults.
These results support the idea that policy solutions to the opioid crisis need to address the effect of PIP on opioidrelated adverse events in older adults.
1 To achieve such solutions will require at least 2 distinct goals. The first goal is to reduce the incidence of new exposures to PIP by changing prescribing habits through prescriber and patient education, regulations, decision support, and other complementary efforts. The second is to implement effective, evidence-based treatment strategies to reduce risk of overdose in older adults exposed to PIP. Individuals exposed to PIP and their prescribers should be offered more monitoring and clinical support, overdose education and naloxone rescue kits, alternative pain treatments, and low-barrier access to treatment for opioid use disorder, if warranted.
Our findings suggest that PIP exposure may have somewhat different, if overlapping, effects in older and younger adults. The fact that PIP may have different origins and different meanings in the 2 groups may, in turn, drive this. PIP is generally considered to involve a mix of inappropriate use (by the patient) and inappropriate and possibly dangerous prescribing (by the provider). In younger adults, the opioid misuse aspect of PIP may be more predominant. In contrast, in older adults, PIP may have more to do with excessively high doses and co-prescribing with benzodiazepines, which may confer risk not through misuse but through use as directed. This points to a need to individualize approaches to reducing new PIP incidence in different populations, particularly those of different ages.
Finding ways to improve outcomes for individuals already exposed to PIP-the second goal above-may be as important as reducing PIP incidence, although it may be receiving less attention. Our findings suggest that PIP is a problem of considerable magnitude and significance in older adults. In Massachusetts, 215,210 older adults were exposed to PIP at least once during the study period. Extrapolating to the entire United States, this indicates that at least 11 million older adults were exposed to PIP during this period. Management of older adults already exposed to PIP will be critical to improving their outcomes, but to our knowledge, there have been no studies of how best to conduct such management. For example, should older adults on high-dose opioids be tapered to less than 100 MMEless than 80, less than 60-and over what period of time? Does tapering reduce risk to individuals who have previously been exposed to PIP, or does it paradoxically increase risk? Answers to these and similar questions would inform a presently evidence-free zone.
We acknowledge the study's limitations. First, like any observational study, ours is subject to residual confounding. This refers to differences between individuals who received opioids with PIP and those who received opioids without PIP that may contribute to differences in outcomes. Although we controlled for some differences in our models, other factors were not measured in this study. Second, population-based results from Massachusetts may not fully generalize to other states. Third, the list of opioids in this study did not include tramadol, which has opioid-like properties and can sometimes cause an opioid use disorder. Finally, opioid overdose deaths may be undercounted, especially in older adults because of increasing plausibility of death from natural causes.
In summary, we found that older age was the strongest predictor of undergoing PIP in people who were prescribed opioids. We also found that PIP was associated with risk of adverse outcomes in older and younger adults. Policy strategies are urgently needed to reduce PIP exposure in older adults and to reduce risk in those already exposed.
